This disclosure relates generally to treating patients having pulmonary hypertension such as pulmonary arterial hypertension (PAH), or symptoms associated therewith, by administering a therapeutically effective amount of ranolazine or a salt or salts thereof to the patient.本揭露內容大致上關於經由投予患者治療上有效量之雷諾嗪(ranolazine)或其鹽或鹽類來治療患有肺性高血壓(諸如肺動脈性高血壓(PAH))或與其相關之症狀的患者。